, Essais cliniques portant sur les dispositifs médicaux et dispositifs médicaux de diagnostic in vitro -ANSM : Agence nationale de sécurité du médicament et des produits de santé
,
, LOI n° 2012-300 du 5 mars 2012 relative aux recherches impliquant la personne humaine, 2012.
Adaptive Designs for Clinical Trials, N Engl J Med. 7 juill, vol.375, issue.1, pp.65-74, 2016. ,
The Large Pharmaceutical Company Perspective, N Engl J Med. 5 janv, vol.376, issue.1, pp.52-60, 2017. ,
Design and analysis of phase I clinical trials, Biometrics. sept, vol.45, issue.3, pp.925-962, 1989. ,
Up-and-down designs for phase I clinical trials, Contemp Clin Trials. sept, vol.36, issue.1, pp.218-245, 2013. ,
Operating characteristics of the standard phase I clinical trial design, Comput Stat Data Anal. 28 mai, vol.30, issue.3, pp.303-318, 1999. ,
Accelerated titration designs for phase I clinical trials in oncology, J Natl Cancer Inst. 6 août, vol.89, issue.15, pp.1138-1185, 1997. ,
Continual reassessment method: a practical design for phase 1 clinical trials in cancer, Biometrics. mars, vol.46, issue.1, pp.33-48, 1990. ,
Phase I-II clinical trial design: a state-ofthe-art paradigm for dose finding, Ann Oncol Off J Eur Soc Med Oncol, vol.01, issue.3, pp.694-703, 2018. ,
Combined criteria for dose optimisation in early phase clinical trials, Stat Med. 27 juin, 2019. ,
,
Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study, J Rheumatol. déc, vol.34, issue.12, pp.2423-2453, 2007. ,
Update of EULAR recommendations for the treatment of systemic sclerosis, Ann Rheum Dis. 1 août, vol.76, issue.8, pp.1327-1366, 2017. ,
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables, J Clin Epidemiol. avr, vol.64, issue.4, pp.383-94, 2011. ,
Trials and tribulations of skin iontophoresis in therapeutics, Br J Clin Pharmacol. janv, vol.77, issue.1, pp.63-71, 2014. ,
Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN, Nature. 27 juill, vol.442, issue.7101, pp.457-60, 2006. ,
What can current stimulation tell us about the vascular function of endogenous prostacyclin in healthy rat skin in vivo?, J Invest Dermatol. janv, vol.131, issue.1, pp.237-281, 2011. ,
Hierarchical evaluation of electrical stimulation protocols for chronic wound healing: An effect size metaanalysis. Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc, vol.25, pp.883-91, 2017. ,
Prostacyclin signaling boosts NADPH oxidase 4 in the endothelium promoting cytoprotection and angiogenesis, Antioxid Redox Signal. 10 juin, vol.20, issue.17, pp.2710-2735, 2014. ,
,
, Presse Medicale Paris Fr, vol.37, issue.2, pp.271-85, 1983.
Cathodal iontophoresis of treprostinil induces a sustained increase in cutaneous blood flux in healthy volunteers, J Clin Pharmacol. janv, vol.53, issue.1, pp.58-66, 2013. ,
Effect of continuous vs pulsed iontophoresis of treprostinil on skin blood flow, Eur J Pharm Sci Off J Eur Fed Pharm Sci. 25 mai, vol.72, pp.21-27, 2015. ,
Cathodal iontophoresis of treprostinil and iloprost induces a sustained increase in cutaneous flux in rats, Br J Pharmacol. févr, vol.162, issue.3, pp.557-65, 2011. ,
Cutaneous iontophoresis of treprostinil in systemic sclerosis: a proof-of-concept study, Clin Pharmacol Ther. avr, vol.95, issue.4, pp.439-484, 2014. ,
Cutaneous iontophoresis of treprostinil, a prostacyclin analog, increases microvascular blood flux in diabetic malleolus area, Eur J Pharmacol. 5 juill, vol.758, pp.123-131, 2015. ,
Treprostinil Iontophoresis in Idiopathic Pulmonary Arterial Hypertension, Am J Respir Crit Care Med, vol.192, issue.8, pp.1014-1020, 2015. ,
,
, Treprostinil Iontophoresis Improves Digital Blood Flow during Local Cooling in Systemic Sclerosis. Microcirc N Y N, vol.23, pp.266-70, 1994.
Vascular Effects of Treprostinil Cutaneous Iontophoresis on the Leg, Finger, and Foot, J Clin Pharmacol, vol.57, issue.9, pp.1215-1235, 2017. ,
EULAR Textbook on Systemic Sclerosis, vol.369, 2013. ,
Cellular and molecular aspects of vascular dysfunction in systemic sclerosis, Nat Rev Rheumatol, vol.6, issue.8, pp.453-60, 2010. ,
Digital ulcers in systemic sclerosis, Rheumatology. janv, vol.56, issue.1, pp.14-25, 2017. ,
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative, Ann Rheum Dis. 11 janv, vol.72, issue.11, pp.1747-55, 2013. ,
Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis, Clin Rheumatol. févr, vol.33, issue.2, pp.207-221, 2014. ,
, Décision du 5 novembre 2007 relative aux bonnes pratiques de préparation. 37. CTCAE Files
Iontophoretic drug delivery, Adv Drug Deliv Rev. 27 mars, vol.56, issue.5, pp.619-58, 2004. ,
Transdermal drug delivery: overcoming the skin's barrier function, Pharm Sci Technol Today. 1 sept, vol.3, issue.9, pp.318-344, 2000. ,
Regional differences in the thickness (cell layers) of the human stratum corneum: an ultrastructural analysis, J Invest Dermatol. avr, vol.62, issue.4, pp.415-437, 1974. ,
Skin barrier defect in atopic dermatitis: increased permeability of the stratum corneum using dimethyl sulfoxide and theophylline, J Dermatol Sci. avr, vol.5, issue.2, pp.92-98, 1993. ,
Modulated iontophoretic delivery of small and large molecules through microchannels, Int J Pharm. 15 sept, vol.434, issue.1-2, pp.106-120, 2012. ,
A Time-Response Model for Analysis of Drug Transport and Blood Flow Response during Iontophoresis of Acetylcholine and Sodium Nitroprusside, J Vasc Res, vol.46, issue.4, pp.270-277, 2009. ,
Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial, J Heart Lung Transplant Off Publ Int Soc Heart Transplant. févr, vol.29, issue.2, pp.137-186, 2010. ,
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial, Am J Respir Crit Care Med. 15 mars, vol.165, issue.6, pp.800-804, 2002. ,
A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis, J Am Acad Dermatol. mai, vol.54, issue.5, pp.880-882, 2006. ,
Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients, J Clin Invest. juill, vol.108, issue.2, pp.241-50, 2001. ,
A: Mean arterial pressure (mmHg) following iontophoresis (min) at each study visit for stage 2 patients. B: Evolution of the cutaneous vascular conductance at each visit for stage 2 patients C: Evolution of the cutaneous temperature (°C) at each study visit for stage 2 patients ,
, Appendix_Table_2 : Iontophoresis and follow-up characteristics of step 2 patients * The duration of follow-up was shortened at the patient's request